GPT and metabolic dysfunction-associated steatotic liver disease: The estimates of NAFLD prevalence for European populations range from 1.3% to 22.5% in children aged 3–18 years, or 11% in children aged 12.4 ± 2.6 years if defined by elevated AST or ALT concentrations more than 50 IU/L [32].